Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

Por Tebbutt, N C, Cummins, M M, Sourjina, T, Strickland, A, Van Hazel, G, Ganju, V, Gibbs, D, Stockler, M, Gebski, V, Zalcberg, J
Publicado em 2010

A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer

Por Michael, M, Price, T, Ngan, S Y, Ganju, V, Strickland, A H, Muller, A, Khamly, K, Milner, A D, Dilulio, J, Matera, A, Zalcberg, J R, Leong, T
Publicado em 2009

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial

Por Tebbutt, N C, Parry, M M, Zannino, D, Strickland, A H, Van Hazel, G A, Pavlakis, N, Ganju, V, Mellor, D, Dobrovic, A, Gebski, V J
Publicado em 2013